XTL Biopharmaceuticals Ltd

XTLB

Company Profile

  • Business description

    XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.

  • Contact

    85 Medinat Hayehudim Street
    Hertzlia4676670
    ISR

    T: +972 542288897

    E: [email protected]

    https://www.xtlbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    5

Stocks News & Analysis

stocks

Nvidia earnings: Business as usual as forecasts suggest that all is well

Are the shares cheap?
stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,932.4064.90-0.72%
CAC 408,146.8369.95-0.85%
DAX 4025,736.24309.13-1.19%
Dow JONES (US)50,314.60444.82-0.88%
FTSE 10010,551.17138.70-1.30%
HKSE23,294.75213.42-0.91%
NASDAQ24,424.2095.810.39%
Nikkei 22559,024.28163.850.28%
NZX 50 Index14,264.2942.67-0.30%
S&P 5007,330.999.54-0.13%
S&P/ASX 2008,821.8061.40-0.69%
SSE Composite Index3,587.833.250.09%

Market Movers